论文部分内容阅读
目的探讨双歧三联活菌胶囊联合阿托伐他汀对高脂血症患者肠道乳酸杆菌数量的影响及疗效观察。方法选取心内科就诊治疗的高脂血症患者86例,随机将其分为观察组(n=43例)和对照组(n=43例)。观察组患者予以双歧三联活菌胶囊联合阿托伐他汀治疗8周,其中双歧三联活菌胶囊420 mg/次,3次/d;阿托伐他汀片10 mg/次,1次/d。对照组患者予以单纯的阿托伐他汀治疗,剂量、方法及疗程同观察组。观察并记录两组患者治疗前后血脂总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平及肠道乳酸杆菌数量的变化。结果治疗8周后,两组患者TC、TG和LDL-C较前均有不同程度下降,HDL-C水平较前均有不同程度上升(P<0.05),且观察组下降或上升幅度较对照组更明显(P<0.05);同时两组患者肠道乳酸杆菌数量较前均有不同程度上升(P<0.05),且观察组上升幅度较对照组更明显(P<0.05)。结论双歧三联活菌胶囊联合阿托伐他汀治疗高脂血症能更明显降低TC、TG和LDL-C水平,升高HDL-C水平,具有良好的调脂效应,可能与其能调整肠道内的微生物菌群,大幅提升肠道乳酸杆菌数量密切相关。
Objective To investigate the effect of bifid triple live bacteria capsule combined with atorvastatin on the number of intestinal lactobacilli in patients with hyperlipidemia and its therapeutic effect. Methods Totally 86 patients with hyperlipidemia treated by cardiology were randomly divided into observation group (n = 43) and control group (n = 43). Patients in the observation group were treated with bifidobacterium triple viable capsule and atorvastatin for 8 weeks, including bifid triple viable capsule 420 mg / time, 3 times / d, atorvastatin tablets 10 mg / time, once / d . Patients in the control group were treated with atorvastatin alone, with the same dosage, method and course of treatment as the observation group. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and the number of lactobacilli in the two groups before and after treatment were observed and recorded The change. Results After 8 weeks of treatment, the levels of TC, TG and LDL-C in both groups dropped to some extent compared with those in the previous two groups, and the level of HDL-C increased to some extent (P <0.05), and the decrease or increase in the observation group (P <0.05). At the same time, the number of intestinal lactobacilli in both groups increased to some extent (P <0.05), and the increase rate in the observation group was more obvious than that in the control group (P <0.05). Conclusion Bifid triple viable capsule combined with atorvastatin treatment of hyperlipidemia can significantly lower TC, TG and LDL-C levels, increased HDL-C levels, has a good lipid-lowering effect, and may be related to its ability to regulate the intestinal Of microbial flora, a significant increase in the number of intestinal lactobacilli are closely related.